XKRX
137310
Market cap571mUSD
Oct 08, Last price
6,410.00KRW
1D
-6.42%
1Q
-0.77%
IPO
-89.15%
Name
SD Biosensor Inc
Chart & performance
P/E
—
P/S
1.08
EPS
—
Div yield, %
—
Shrs. gr., 5y
3.45%
Rev. gr., 5y
-15.87%
Revenues
710.58b
+2.30%
Net income
-521.41b
L+429.83%
CFO
357.52b
+128.41%
Dividend
Mar 30, 2026200 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SD Biosensor Inc is an in vitro diagnostic company. It is engaged in the immunochemical diagnosis, molecular diagnosis, point-of-care diagnosis (POCTs), and self blood glucose measurement business. The company researches and develops products such as rapid immunochemical diagnosis products, immunochemical fluorescence diagnosis products, molecular diagnosis products, and enzyme immunological reaction diagnosis products.
Key people
Yeong Sik Cho
Chairman
Won Gi Min
President
Hyo Geun Lee
Co-Chief Executive Officer, Director · since 2021
Ho Gyeong Yoo
Chief Financial Officer, Assistant Managing Director · since 2023
Hye Yim Cho
Vice President, Director · since 2025
Yun Seok Jin
Managing Director · since 2023
Won Seok Joo
Assistant Managing Director · since 2024
Ju Han Kim
Assistant Managing Director · since 2024
Seong Ho Kim
Assistant Managing Director · since 2022
Seok Ju Lee
Assistant Managing Director · since 2025
Seon Yeong Lee
Assistant Managing Director
Seong Jin Park
Assistant Managing Director · since 2021
Tae Yeong Huh
Co-Chief Executive Officer, Director · since 2021
Sang Gyun Cha
Non-Executive Independent Director
Seong Hwan Choi
Non-Executive Independent Director · since 2020
Yeong Gyeong Lee
Non-Executive Independent Director · since 2025
Wu Chang Lee
Non-Executive Independent Director · since 2022
Jae Gyu Park
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||